Information  X 
Enter a valid email address

Accrol Group Hldgs (ACRL)

  Print   

Tuesday 27 October, 2020

Accrol Group Hldgs

Result of AGM

RNS Number : 3780D
Accrol Group Holdings PLC
27 October 2020
 

27 October 2020

 

Accrol Group Holdings plc

("Accrol", the "Company" or the "Group")

AIM: ACRL

 

Result of 2020 Annual General Meeting

 

Accrol, the leading independent tissue converter in the UK, announces that all of the resolutions set out in the Notice of AGM were passed by the requisite majority at the Company's AGM, held earlier today.

 

Details of the proxy votes received by the Company are as follows:

 

Resolution

For

Against

Total

Withheld


No. of votes

%

No. of votes

%

No. of votes

%

No. of votes

1.  To receive the Annual Report and Accounts

88,325,741

99.95

42,452

0.05

88,368,193

100

0

2.  To re-appoint BDO as Auditor

84,380,997

95.58

3,906,087

4.42

88,287,084

100

81,109

3.  To approve the Directors' Remuneration Report

49,361,817

77.92

13,987,854

22.08

63,349,671

100

25,018,522

4.  To authorise the Directors to allot relevant securities

84,363,491

99.83

141,407

0.17

84,504,898

100

3,863,295

5.  To authorise the Directors to allot equity securities for cash without making a pre-emptive offer to shareholders*

88,222,985

99.84

141,407

0.16

88,364,392

100

3,801

 

*Special resolution

 

Notes:

 

 

1.

Proxy appointments which gave discretion to the Chairman of the AGM have been included in

"For" total for the appropriate resolution.

 

2.

Votes "For" and "Against" any resolution are expressed as a percentage of votes validly cast for that resolution.

 

3.

A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against".

 

4.

The number of shares in issue on 27 October 2020 was 195,246,536 with no shares in treasury.

 

5.

The full text of the resolutions passed at the AGM can be found in the Notice of Annual General Meeting which is available on the Company's website at www.accrol.co.uk.

 

 

In compliance with the QCA Code, the Board notes the percentage of votes cast against Resolution 3 to approve the Directors' Remuneration Report. The Board has already engaged in discussions with shareholders and continues to maintain a healthy dialogue with its investors.

 

For further information, please contact:

 

 

 

Accrol Group Holdings plc

 

Dan Wright, Executive Chairman

Via Belvedere Communications

Gareth Jenkins, Chief Executive Officer

 

 

 

Zeus Capital Limited (Nominated Adviser & Broker) 

 

Dan Bate / Jordan Warburton

Tel: +44 (0) 161 831 1512

Dominic King / John Goold

Tel: +44 (0) 203 829 5000



Liberum Capital Limited (Joint Broker)

Tel: +44 (0) 20 3100 2222

Clayton Bush / Edward Thomas




Belvedere Communications Limited

 

Cat Valentine

Tel: +44 (0) 7715 769 078

Keeley Clarke

Tel: +44 (0) 7967 816 525


[email protected]

 

Notes to Editors

 

Accrol Group Holdings plc, based in Lancashire, is a leading tissue converter and supplier of toilet tissues, kitchen rolls and facial tissues, as well as other tissue products, to major discounters and grocery retailers throughout the UK. The business operates from four sites in Lancashire:

 

·

A manufacturing, storage, and distribution facility in Blackburn;

·

A storage and administrative centre in Blackburn;

·

A facial tissue plant, also in Blackburn; and

·

A manufacturing, storage, and distribution facility in Leyland.

 

For more information, please visit www.accrol.co.uk .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGUBSSRRUURUAA

a d v e r t i s e m e n t